

Expected Launch Dates of Generic Versions

Brand	Generic	Annual Brand Sales
2009 Expected Releases		
Ambien CR [®]	Zolpidem tartrate	\$946M
Cardizem LA [®]	Diltiazem HCL	\$115M
Doryx [®]	Doxycycline hyclate	\$151M
Evista [®]	Raloxifene HCL	\$1.07B
Femhrt [®]	Ethinyl estradiol; norethindrone	\$580M
Suboxone [®]	Buprenorphone/Naloxone ODT Tablets	\$550M
Ultram [®] ER	Tramadol hydrochloride	TBD
Valtrex [®]	Valacyclovir hydrochloride	\$1.6B

All estimated launch dates are subject to change as a result of litigations and patent exclusivities. Patent expiration dates may not imply generic availability.

Ambien CR[®] is a registered trademark of Sanofi-Aventis.

Cardizem LA[®] is a registered trademark of Biovail.

Doryx[®] and Femhrt[®] are registered trademarks of Warner Chilcott.

Evista[®] is a registered trademark of Eli Lilly.

Suboxone[®] is a registered trademark of Reckitt Benckiser.

Ultram[®] ER is a registered trademark of Ortho-McNeil.

Valtrex[®] is a registered trademark of GlaxoSmithKline.